Sugi Predict

Sugi Predict / Targets / PSMA1

PSMA1

Proteasome subunit alpha type-1 · P25786 · PSMA1 on Sugi Atlas →

23,962 patent compounds predicted against PSMA1, 16,535 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL605949 SCHEMBL605949 0.54 15/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL609327 SCHEMBL609327 0.55 12/20
SCHEMBL607553 SCHEMBL607553 0.54 12/20
SCHEMBL606932 SCHEMBL606932 0.53 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL609081 SCHEMBL609081 0.52 12/20
SCHEMBL606926 SCHEMBL606926 0.52 12/20
SCHEMBL606344 SCHEMBL606344 0.51 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1327404 SCHEMBL1327404 0.50 12/20
SCHEMBL607035 SCHEMBL607035 0.61 11/20
SCHEMBL609733 SCHEMBL609733 0.60 11/20
SCHEMBL609324 SCHEMBL609324 0.60 11/20
SCHEMBL605158 SCHEMBL605158 0.59 11/20
SCHEMBL606315 SCHEMBL606315 0.59 11/20
SCHEMBL609290 SCHEMBL609290 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20

Clinical trials — most relevant to PSMA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy PHASE4RECRUITING
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy PHASE2/PHASE3RECRUITING
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients PHASE3COMPLETED
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function PHASE2ACTIVE_NOT_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer PHASE1/PHASE2COMPLETED
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer PHASE2COMPLETED
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan PHASE2COMPLETED
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors PHASE1COMPLETED
The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma PHASE1RECRUITING
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 PHASE1COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Head-to-head Comparison of 68Ga-PSMA-11 and 18F-PSMA-1007 nanCOMPLETED
[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer nanACTIVE_NOT_RECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer. nanSUSPENDED
Prostate Specific Antigen Levels of Individuals Living in Rural Areas nanNOT_YET_RECRUITING
Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PSMA1 binder may also engage these)

ProteinNameSimilarity
Q5REN2 — 1.000 Q5REN2 →
Q3T0X5 — 1.000 Q3T0X5 →
Q4R3H2 — 1.000 Q4R3H2 →
P18420 — 1.000 P18420 →
Q9R1P4 — 1.000 Q9R1P4 →
O42265 — 1.000 O42265 →
Q27488 — 1.000 Q27488 →
O14250 — 1.000 O14250 →
Q24178 — 1.000 Q24178 →
O44156 — 1.000 O44156 →
O16811 — 1.000 O16811 →
PSMA2 Proteasome subunit alpha type-2 0.999 landscape →
O23712 — 0.998 O23712 →
P52428 — 0.998 P52428 →
Q9V5C6 — 0.998 Q9V5C6 →
Q9GU37 — 0.998 Q9GU37 →
P12881 — 0.998 P12881 →
Q8SRU7 — 0.997 Q8SRU7 →
Q27563 — 0.997 Q27563 →
O59770 — 0.997 O59770 →
O81148 — 0.997 O81148 →
P49722 — 0.997 P49722 →
P17220 — 0.997 P17220 →
O96788 — 0.996 O96788 →
Q54XM7 — 0.996 Q54XM7 →
P22769 — 0.996 P22769 →
P18422 — 0.996 P18422 →
O16812 — 0.996 O16812 →
P21242 — 0.996 P21242 →
P40303 — 0.996 P40303 →